Pfizer has reaffirmed its full-year 2026 financial guidance, which was originally introduced on December 16, 2025. The company confirmed its outlook following a separate announcement regarding a transition in its Chief Financial Officer (CFO) position on June 18, 2026.
Key Details
- Reaffirmed 2026 Revenue: Expected to be in the range of $59.5 billion to $62.5 billion.
- Reaffirmed 2026 Adjusted Diluted EPS: Expected to be in the range of $2.80 to $3.00.
- Context: The reaffirmation was issued to provide stability and confirm the company's financial outlook following the announcement of a CFO change.